Lithium and renal and upper urinary tract tumors: results from a nationwide population-based study

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Lithium and renal and upper urinary tract tumors : results from a nationwide population-based study. / Kessing, Lars Vedel; Gerds, Thomas Alexander; Feldt-Rasmussen, Bo; Andersen, Per Kragh; Licht, Rasmus W.

I: Bipolar Disorders, Bind 17, Nr. 8, 12.2015, s. 805-13.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Kessing, LV, Gerds, TA, Feldt-Rasmussen, B, Andersen, PK & Licht, RW 2015, 'Lithium and renal and upper urinary tract tumors: results from a nationwide population-based study', Bipolar Disorders, bind 17, nr. 8, s. 805-13. https://doi.org/10.1111/bdi.12344

APA

Kessing, L. V., Gerds, T. A., Feldt-Rasmussen, B., Andersen, P. K., & Licht, R. W. (2015). Lithium and renal and upper urinary tract tumors: results from a nationwide population-based study. Bipolar Disorders, 17(8), 805-13. https://doi.org/10.1111/bdi.12344

Vancouver

Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Lithium and renal and upper urinary tract tumors: results from a nationwide population-based study. Bipolar Disorders. 2015 dec.;17(8):805-13. https://doi.org/10.1111/bdi.12344

Author

Kessing, Lars Vedel ; Gerds, Thomas Alexander ; Feldt-Rasmussen, Bo ; Andersen, Per Kragh ; Licht, Rasmus W. / Lithium and renal and upper urinary tract tumors : results from a nationwide population-based study. I: Bipolar Disorders. 2015 ; Bind 17, Nr. 8. s. 805-13.

Bibtex

@article{e6a60b709ece4f838b38b44852b3428f,
title = "Lithium and renal and upper urinary tract tumors: results from a nationwide population-based study",
abstract = "OBJECTIVES: A recent alarming finding suggested an increased risk of renal tumors among long-term lithium users. The objectives of the present study were to estimate rates of renal and upper urinary tract tumors (RUT), malignant and benign, among individuals exposed to successive prescriptions for lithium, anticonvulsants, and other psychotropic agents used for bipolar disorder, and among unexposed individuals.METHODS: This was a nationwide, population-based longitudinal study including time-specific data from all individuals exposed to lithium (n = 24,272) or anticonvulsants (n = 386,255), all individuals with a diagnosis of bipolar disorder (n = 9,651), and a randomly selected sample of 1,500,000 from the Danish population. The study period was from 1995 to 2012, inclusive. Outcomes were hazard rate ratios (HR) for RUT in three groups: (i) combined malignant and benign, (ii) malignant, and (iii) benign. Analyses were adjusted for the number of prescriptions for lithium/anticonvulsants, antipsychotic agents, antidepressants, and use of all other types of medication; age; gender; employment status; calendar year; and a diagnosis of bipolar disorder.RESULTS: Continued treatment with lithium was not associated with increased rates of RUT [adjusted HR malignant or benign: 0.67-1.18, p (trend) = 0.70; adjusted HR malignant: 0.61-1.34, p (trend) = 0.90; adjusted HR benign: 0.74-1.18, p (trend) = 0.70]. Similarly, continued treatment with anticonvulsants was not associated with increased rates of RUT [adjusted HR malignant or benign: 0.97-1.18, p (trend) = 0.10; adjusted HR malignant: 0.82-1.15, p (trend) = 0.80; adjusted HR benign: 0.94-1.36, p (trend) = 0.20]. The associations were confirmed among the 9,651 patients with a diagnosis of bipolar disorder.CONCLUSIONS: Treatment with lithium is not associated with increased rates of RUT.",
author = "Kessing, {Lars Vedel} and Gerds, {Thomas Alexander} and Bo Feldt-Rasmussen and Andersen, {Per Kragh} and Licht, {Rasmus W}",
note = "{\textcopyright} 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2015",
month = dec,
doi = "10.1111/bdi.12344",
language = "English",
volume = "17",
pages = "805--13",
journal = "Bipolar Disorders, Supplement",
issn = "1399-2406",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Lithium and renal and upper urinary tract tumors

T2 - results from a nationwide population-based study

AU - Kessing, Lars Vedel

AU - Gerds, Thomas Alexander

AU - Feldt-Rasmussen, Bo

AU - Andersen, Per Kragh

AU - Licht, Rasmus W

N1 - © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2015/12

Y1 - 2015/12

N2 - OBJECTIVES: A recent alarming finding suggested an increased risk of renal tumors among long-term lithium users. The objectives of the present study were to estimate rates of renal and upper urinary tract tumors (RUT), malignant and benign, among individuals exposed to successive prescriptions for lithium, anticonvulsants, and other psychotropic agents used for bipolar disorder, and among unexposed individuals.METHODS: This was a nationwide, population-based longitudinal study including time-specific data from all individuals exposed to lithium (n = 24,272) or anticonvulsants (n = 386,255), all individuals with a diagnosis of bipolar disorder (n = 9,651), and a randomly selected sample of 1,500,000 from the Danish population. The study period was from 1995 to 2012, inclusive. Outcomes were hazard rate ratios (HR) for RUT in three groups: (i) combined malignant and benign, (ii) malignant, and (iii) benign. Analyses were adjusted for the number of prescriptions for lithium/anticonvulsants, antipsychotic agents, antidepressants, and use of all other types of medication; age; gender; employment status; calendar year; and a diagnosis of bipolar disorder.RESULTS: Continued treatment with lithium was not associated with increased rates of RUT [adjusted HR malignant or benign: 0.67-1.18, p (trend) = 0.70; adjusted HR malignant: 0.61-1.34, p (trend) = 0.90; adjusted HR benign: 0.74-1.18, p (trend) = 0.70]. Similarly, continued treatment with anticonvulsants was not associated with increased rates of RUT [adjusted HR malignant or benign: 0.97-1.18, p (trend) = 0.10; adjusted HR malignant: 0.82-1.15, p (trend) = 0.80; adjusted HR benign: 0.94-1.36, p (trend) = 0.20]. The associations were confirmed among the 9,651 patients with a diagnosis of bipolar disorder.CONCLUSIONS: Treatment with lithium is not associated with increased rates of RUT.

AB - OBJECTIVES: A recent alarming finding suggested an increased risk of renal tumors among long-term lithium users. The objectives of the present study were to estimate rates of renal and upper urinary tract tumors (RUT), malignant and benign, among individuals exposed to successive prescriptions for lithium, anticonvulsants, and other psychotropic agents used for bipolar disorder, and among unexposed individuals.METHODS: This was a nationwide, population-based longitudinal study including time-specific data from all individuals exposed to lithium (n = 24,272) or anticonvulsants (n = 386,255), all individuals with a diagnosis of bipolar disorder (n = 9,651), and a randomly selected sample of 1,500,000 from the Danish population. The study period was from 1995 to 2012, inclusive. Outcomes were hazard rate ratios (HR) for RUT in three groups: (i) combined malignant and benign, (ii) malignant, and (iii) benign. Analyses were adjusted for the number of prescriptions for lithium/anticonvulsants, antipsychotic agents, antidepressants, and use of all other types of medication; age; gender; employment status; calendar year; and a diagnosis of bipolar disorder.RESULTS: Continued treatment with lithium was not associated with increased rates of RUT [adjusted HR malignant or benign: 0.67-1.18, p (trend) = 0.70; adjusted HR malignant: 0.61-1.34, p (trend) = 0.90; adjusted HR benign: 0.74-1.18, p (trend) = 0.70]. Similarly, continued treatment with anticonvulsants was not associated with increased rates of RUT [adjusted HR malignant or benign: 0.97-1.18, p (trend) = 0.10; adjusted HR malignant: 0.82-1.15, p (trend) = 0.80; adjusted HR benign: 0.94-1.36, p (trend) = 0.20]. The associations were confirmed among the 9,651 patients with a diagnosis of bipolar disorder.CONCLUSIONS: Treatment with lithium is not associated with increased rates of RUT.

U2 - 10.1111/bdi.12344

DO - 10.1111/bdi.12344

M3 - Journal article

C2 - 26534877

VL - 17

SP - 805

EP - 813

JO - Bipolar Disorders, Supplement

JF - Bipolar Disorders, Supplement

SN - 1399-2406

IS - 8

ER -

ID: 157490874